DDC and schizophrenia: In psychiatric disorders such as schizophrenia, decreasing tryptamine levels by reducing AADC activity, stimulating AHR signalling, and carefully inhibiting MAO activity may improve neurotransmitter balance, reduce neuroinflammation, and enhance cognitive function, potentially providing new treatment options for this complex disorder.